Short Bowel Syndrome Treatment Protocol
Introduction to Teduglutide
- Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves intestinal absorption and promotes weaning from parenteral nutrition (PN) in patients with short bowel syndrome (SBS), according to the American Gastroenterological Association 1
- Teduglutide increases intestinal villus height and crypt depth, enhancing intestinal absorption, as stated by the European Society for Clinical Nutrition and Metabolism 2, 3
- It increases wet weight absorption by approximately 750g/day, with a limited effect on energy absorption (<250 kcal/day), as reported by the European Society for Clinical Nutrition and Metabolism 2, 3
Treatment Protocol
Pre-Treatment Evaluation
- A colonoscopy should be performed before starting treatment to confirm the absence of colorectal polyps or malignancies, as recommended by the American College of Gastroenterology 1, 4
- Teduglutide is contraindicated in patients with active gastrointestinal malignancies, according to the National Comprehensive Cancer Network 1
- Patients with a history of non-gastrointestinal malignancies (especially within 5 years) should avoid using teduglutide, as advised by the American Society of Clinical Oncology 1
Monitoring
- Regular colonoscopies should be performed to monitor for polyps or malignancies, as recommended by the American College of Gastroenterology 1, 4
- Parenteral nutrition should be adjusted and tapered in a planned manner, according to the American Society for Parenteral and Enteral Nutrition 1
Clinical Efficacy and Safety
- Teduglutide may increase the risk of growing gastrointestinal polyps or malignancies due to its growth factor properties, as warned by the American Gastroenterological Association 1, 4
- Long-term use of teduglutide requires continuous monitoring for tumor promotion risk, as stated by the European Society for Clinical Nutrition and Metabolism 2, 3
Treatment Positioning
- Teduglutide should be used only in carefully selected patients after optimizing dietary therapy and conventional short bowel syndrome treatment, as recommended by the American Gastroenterological Association 1, 4
- Teduglutide should be prescribed by experienced physicians and used in facilities where objective evaluation is possible, according to the European Society for Clinical Nutrition and Metabolism 4, 5
- Patients should be fully informed about the benefits (possibility of parenteral nutrition weaning, improvement in quality of life) and risks (adverse effects, long-term safety concerns) of teduglutide treatment, as advised by the American College of Gastroenterology 1, 4
Safety Profile and Surveillance Recommendations for Teduglutide (GLP‑2 Analog)
Overall Tolerability and Malignancy Surveillance
- Teduglutide is generally well tolerated, with adverse effects mainly confined to the gastrointestinal tract; however, patients require lifelong endoscopic surveillance for gastrointestinal malignancy because of a potential tumor‑promoting risk. 6